Does PCOS Cause Hair Loss? What Actually Decides

Medically reviewed by our internal dermatology committee.

The short answer

It can, in roughly one in five cases — and the hair is not what gets the condition diagnosed.

Both halves of that sentence matter. Pooled data from twenty-four studies puts female pattern hair loss at about 22.7% among women with polycystic ovary syndrome, which is common enough to take seriously and far from inevitable. Meanwhile, the diagnosis itself turns on your cycles and on body hair, not on your scalp. A guideline recommendation states plainly that scalp thinning on its own, without excess body hair, is a relatively weak predictor of measurable androgen excess.

So if you have come here hoping your hair will finally explain something, the honest answer is that it will point, not prove. The rest of this page is about what does the proving, and what you can do for your scalp in the meantime — which, usefully, does not have to wait for anyone’s answer.

Androgens push hair in two directions

Start with the paradox, because everything else follows from it.

When androgens run high in a woman, two things happen to hair at once, and they run opposite ways. On the chin, the upper lip, the lower abdomen, fine pale vellus hairs thicken, darken and lengthen into terminal hairs — that is hirsutism. On the crown and along the parting, terminal hairs do the reverse. They narrow, shorten, lose pigment, and stop covering the scalp. That is miniaturization.

One hormone. Two opposite outcomes. It only sounds contradictory while you are thinking in hormone levels. Think in follicles instead and it resolves immediately: the signal is the same everywhere, and what differs is what each follicle does with it. A chin follicle answers androgen by growing. A crown follicle answers by shrinking. A follicle at the back of the head barely answers at all — which is exactly why the occipital area is the donor zone in hair transplant surgery.

The diagram below sets the territories side by side, with what the same signal produces in each.

Swipe →

Four territories, four answers to one signal. Pick the one that worries you.

What the diagram shows

Androgen excess does not "make hair fall out" uniformly. It enlarges the follicles that answer by enlarging, shrinks the ones that answer by shrinking, and leaves the rest alone. That is how one woman ends up with too much hair on her chin and too little along her parting — and it is also why a normal blood level tells you nothing about what your scalp is doing. The number measures what circulates, not the sensitivity of what receives it.

The correction

Aim at the right floor. Acting on the hormone is endocrine work, and it gets decided in a consultation. Acting on the miniaturization across the top of the scalp does not wait on a lab result: the only family the expert committee cited in the sources puts first for this pattern in women is topical minoxidil. It is a drug, and its own carton asks you to know the reason for your hair loss before you open it.

See minoxidil solutions for women →

Affiliate link

Read this first: it is a drug, not a cosmetic. Its own labeling says not to use it if your hair loss is sudden or patchy, if it is associated with childbirth, or if you do not know the reason for it, and warns that it may be harmful if used while pregnant or breastfeeding. Which strength suits you, and whether to start at all, is a conversation with a doctor or a pharmacist.

Hold on to the consequence, because it is what a clinician is weighing: the two hair signs are not equivalent evidence. One grows, one retreats, and they carry very different diagnostic weight. Section 4 is where that gets concrete.

Why a normal testosterone result settles nothing

Here is the finding that changes how you should read your own lab work, and it comes from a committee that brought dermatologists and endocrinologists together on this exact question.

Most women with the classic pattern — thinning across the top, a widening parting, the frontal hairline preserved — have normal circulating androgens. The same committee pushes the point further, and the argument is hard to get around: this pattern has been reported in women with no circulating androgens at all, and in women whose androgen receptor does not function. You can have precisely this hair without the hormone it gets blamed on.

Their conclusion is blunt. Isolated hair loss of this type, with normal androgen levels, should not be labelled hyperandrogenism, because it isn’t one.

Two things follow, and they pull in opposite directions, which is why you need both.

A normal hormone panel does not clear your hormones in the broad sense. It tells you the concentration in your blood sits inside the reference range. It says nothing about how your scalp responds to the androgens that are there, and follicular sensitivity is not something a laboratory measures.

But a normal panel also does not sentence you to hunting forever for a hidden imbalance. The same committee holds that every woman presenting with this pattern should be assessed for androgen excess — once, properly — and then adds a list that gets skipped far too often: vitamin D, iron, zinc, thyroid hormones, prolactin. Ordinary tests, all of them. Far more often than testosterone, that is where something correctable turns up.

Two of three, and where your hair sits

Knowing how the diagnosis is actually made will keep you from leaving an appointment feeling dismissed.

In adults, the 2023 international guideline asks for two of three features: infrequent or absent periods; hyperandrogenism, either clinical or measured; and polycystic ovarian morphology on ultrasound, or a raised anti-Müllerian hormone level.

Three details are each worth months of saved time.

First. When cycles are irregular and hyperandrogenism is present, an ovarian ultrasound is not required for the diagnosis, and neither is an AMH level. Two criteria are already met; the third adds nothing. Plenty of women wait months for imaging that, in their particular case, will not decide anything.

Second, and this is the part about your hair. That second criterion can be satisfied in more than one way, and the ways are not equal. Hirsutism on its own is treated as predictive of both biochemical hyperandrogenism and the syndrome in adults — it gets scored on a standardized scale, with the threshold set between 4 and 6 depending on ethnicity. Female pattern hair loss and acne in isolation, without hirsutism, are relatively weak predictors of biochemical hyperandrogenism. That is the guideline’s own wording, and it grades its own certainty as low.

None of which means you should downplay your shedding. The same document explicitly asks that excess hair growth and female pattern hair loss be taken in the history and on examination, and treated as important regardless of how severe they look. What changes is the job they do. Your hair is a perfectly legitimate reason to be in the room; it is simply not the thing that opens the file. Your cycles are, and your body hair if there is any.

Third. In adolescents, neither ultrasound nor AMH is recommended, because specificity is poor at that age. A teenager whose periods are settling in irregularly does not need a picture of her ovaries to be taken seriously.

💡 Elena S. on this: “The first thing I ask for has nothing to do with hormones: the dates of your last twelve cycles, or an honest admission that you never wrote them down. In nine years I have never seen a case move faster than one where the woman arrived with a calendar and two dated photos of her parting. I have seen a great many appointments go nowhere because the only thing brought along was worry — real, but with nothing to grip.”

What the pooled numbers support

Figures on this topic circulate without their error bars, which lends them a precision they do not have. A systematic review published in 2025 pulled together twenty-four observational studies and measured the link in both directions. Read it with the intervals attached, because that is where the information is.

Among women with the syndrome, pooled prevalence of female pattern hair loss came to 22.7%, across eighteen studies and nearly three thousand five hundred patients with a median age of twenty-five. The confidence interval runs from 16.9% to 29.7%, and the authors grade certainty as low on account of what they call very serious inconsistency between studies.

Running the other way — women presenting for female pattern hair loss — pooled prevalence of the syndrome reached 32.3%. That figure rests on six studies, and its interval stretches from 13.6% to 59.1%, with certainty graded very low. An interval that wide does not mean the number is invented. It means nobody can tell you whether to think “one woman in seven” or “one in two”.

Two usable conclusions. The association is real in both directions, and strong enough that established thinning in a young woman earns a question about her periods. And it is nowhere near precise enough to turn a group statistic into a personal explanation. Close to eight in ten women with the syndrome do not have this pattern of hair loss — that is also what this review found, and it is worth saying to anyone who heard her diagnosis as a scheduled sentence for her hair.

The condition was renamed in 2026

If you have searched this subject lately and hit an acronym you did not recognize, nothing has gone wrong. The name changed in May 2026.

Following a multistep global consensus process published in The Lancet, polycystic ovary syndrome was renamed polyendocrine metabolic ovarian syndrome, or PMOS. More than fifty patient and professional organizations took part, among them the Endocrine Society, and more than twenty thousand people were surveyed. The authors call the old name inaccurate and hold it partly responsible for delayed diagnosis, fragmented care and the stigma that travels with both.

The objection is specific, and it should interest anyone who came here about her hair. The word “polycystic” names an image, and the image is not of cysts. What ultrasound picks up is a large number of immature ovarian follicles, not pathological cavities. For decades the name aimed everyone’s attention — patients and clinicians alike — at the least decisive member of the diagnostic trio, the one we just saw becomes unnecessary the moment the other two are present.

Which has an immediate practical edge. If you were ever told “your ovaries look normal on the scan, so it isn’t that”, the sentence did not hold up, and the rename exists partly so it stops being said. The new name puts the endocrine and metabolic axis first, where the condition actually lives.

The old acronym will stay in circulation for a while — the paper allows for a transition of several years — which is why this article keeps both. A chart note or a prescription that says PCOS in 2027 is not describing a different disease.

Is your shedding coming from here?

Everything above describes mechanisms and criteria. You have a specific head of hair, a specific cycle, and an appointment to get or to prepare for. Four questions are enough to tell whether the hormonal lead deserves to go first — and in several cases, why something else should.

The sentence printed on the bottle

Two jobs run in parallel here, and they do not compete. The syndrome itself is managed with an endocrinologist or a gynecologist, it reaches far past your hair, and nothing decided there belongs in an article. Your scalp is the second job, and that one I can talk about.

On the scalp, the order of operations has been stable for years. The expert committee cited above puts topical 5% minoxidil first for this pattern in women, and keeps 5-alpha-reductase inhibitors and antiandrogens for severe or frankly hyperandrogenic cases — in other words, for a medical decision taken after an examination.

One point matters more than it looks: topical treatment does not wait for the work-up. A full endocrine pathway takes months, and follicles keep narrowing through all of them. There is no reason to suspend what is documented while waiting on an answer that will not change how the scalp is handled either way.

There is, however, a reason to read the carton, because the useful part is printed on it. Topical minoxidil is a drug, not a cosmetic. The U.S. over-the-counter label warns that it may be harmful if used while pregnant or breastfeeding; that you should not use it if your hair loss is sudden and/or patchy, if your hair loss is associated with childbirth, or — and this is the line worth framing — if you do not know the reason for your hair loss. It tells you to stop and ask a doctor if you see no regrowth in six months, and one version of the label states outright that the product will not work for all women.

Read that sequence again. The most ordinary drug on the shelf demands, on its own box, the diagnosis this article is sending you to go and get. Application detail, the shedding of the first few weeks and the question of staying on it long-term are covered in Minoxidil 5% for Men: Protocol, Results & Shedding Phase Explained — written for men, but the mechanism and the application rules do not change with sex. For the oral route, spironolactone is covered in Menopause Hair Loss Treatment: Natural Protocol for Women Over 50, and finasteride in Finasteride for Hair Loss: What the Evidence Actually Shows.

If your hair is mostly fine rather than visibly sparse in one area, the density routine, the peptides and the massage evidence are gathered in How to Thicken Fine Hair: The Ultimate Guide for Women.

Pregnancy, and the two drugs that matter

This is not boilerplate. The population this syndrome affects is precisely women of reproductive age, and a good share of them reach a hair appointment in the middle of fertility treatment. Timing changes everything.

Topical minoxidil carries the warning quoted above: it may be harmful if used while pregnant or breastfeeding. That is not soft language to be talked down — it is what the manufacturer is required to print. With finasteride there is no discussion at all: it is contraindicated in women who are or may become pregnant, because of the risk to a male fetus, and the caution extends to handling a broken or crushed tablet. A blister pack is not shared within a couple.

What remains available in that window is not nothing. Correctable causes still get corrected — low ferritin late in pregnancy or after delivery is common, and it is treatable. Management of the syndrome itself follows its own logic with your pregnancy plans built in. And visible density can be recovered the same morning, by a route with no drug status and no effect on the follicle at all: camouflage.

Which camouflage family works on which zone, and the one rule that decides it, are in Do Hair Building Fibers Work? What Holds, and Where It Fails.

What looks like this and isn’t

Pinning your shedding on the syndrome once you carry the diagnosis is the most natural reflex there is, and it is also the most common way to lose a year. Three pictures get confused with it, and each has its own exit.

Heavy diffuse shedding that appeared over a few weeks. That is not the tempo of androgenic miniaturization, which is measured in years. Losing hair by the handful, all over the head, points instead to the whole hair cycle letting go at once: low iron, thyroid, the aftermath of a fever, a restrictive diet, a recently started medication. The single most useful piece of information is the start date, because the trigger usually sits two to four months earlier. The full pathway is in Chronic Telogen Effluvium: Recovery Timeline & Treatments.

Shedding after childbirth. It runs on its own calendar, it usually reverses, and it does not need to be reinterpreted in light of a hormonal diagnosis. The markers are in Postpartum Hair Loss: When Should You Actually Worry?.

Loss exactly where the tension is. Temples and edges, in someone who wears tight styles, braids or extensions: the geography is wrong for the crown, and the cause is mechanical. We treat it separately, with its own window of opportunity, on our traction alopecia pages.

One subtler confusion: the pill. Many women notice shedding and irregular cycles in the months after stopping hormonal contraception, and it is genuinely hard to separate, in the moment, what belongs to coming off a drug from what the drug was covering up. That is a real reason to book an appointment rather than a verdict, and it is also why androgen levels measured while on hormonal contraception are interpreted with care. Just write the dates down; your clinician will know what to do with them.

In every one of these cases, one measurement beats any amount of impression, and it is free: dated photos, same framing, same light, parting clearly visible. The counting method and what it can and cannot show are in How Many Hairs a Day Is Normal to Lose? And How to Count Properly.

Limits, and when to see someone

What this article does not do, and cannot: diagnose you. The syndrome is recognized on criteria that require a history, an examination and lab results read together, and no set of questions online substitutes for that. You will find no dosage here, no numbered protocol, and no suggestion to start or stop any treatment — those belong to the clinician who follows you.

Three further limits, stated plainly.

Topical treatment acts on miniaturization, not on its hormonal cause. It replaces no follow-up, and this syndrome has consequences that reach well beyond hair density — metabolic, gynecological, cardiovascular. That is the specialist’s work, and it is the reason the new name leans on the word “metabolic”.

The evidence here is modest. The 2025 review grades its own certainty as low to very low, and the 2023 guideline grades several of its own statements the same way. Be wary of any source handing you crisper figures than those; they came from nowhere.

And no supplement, oil or device corrects androgen excess. The products mentioned in this article address visible density or miniaturization, and that is all they address.

Some presentations deserve prompt attention before any cosmetic step: a well-defined bare patch that appeared within weeks, a scalp that is red, scaly or painful, loss of eyebrows or eyelashes, sudden shedding by the handful. To those add the ones pointing at the hormonal or metabolic axis: no period for more than three months outside pregnancy, body hair appearing quickly, a deepening voice, unexplained weight gain, unusual fatigue. Most of these are not emergencies. None of them gets solved in the hair aisle.

Frequently asked questions

Will my hair grow back if the syndrome is treated?

Nobody can promise that, and I won’t. What is documented is that miniaturization is gradual: a shrunken follicle can still respond, a lost one cannot. That argues for acting on the scalp early, independently of everything else. But treatment of the syndrome pursues its own goals — cycles, fertility, metabolic health — and no study supports quoting anyone a specific hair gain.

Should I ask my doctor for a testosterone test?

Assessment for androgen excess is part of the recommended work-up for this pattern, so the question is fair. Two caveats. The test carries most value when clinical signs are slight or absent; where there is clear hirsutism, that sign is already predictive on its own. And a normal result, as we saw, does not close the file. What helps your clinician most is not a request for one number — it is your cycle history.

My ovarian ultrasound was normal. Why is this still being discussed?

Because ovarian morphology is one criterion of three, and it is not compulsory. If your cycles are irregular and hyperandrogenism is present, the 2023 guideline says explicitly that ultrasound is not required for the diagnosis. It is one of the stated reasons for renaming the condition in 2026.

I have coarse chin hair but my hair is still thick. Should I worry about my scalp?

Not automatically. The two signs share a possible cause but not a fate: per the 2025 review, a little over two women in ten with the syndrome have the pattern hair loss. Body hair is, however, the sign that counts most in the room, because it is predictive. If it is establishing itself, that is a good reason to ask the question — thick hair or not.

Are PCOS and PMOS two different things?

No, one syndrome under two names. The second was adopted in May 2026 after an international consensus, and the first will stay in circulation through the transition. A medical document using either is describing the same condition.

Can a “hormone balance” supplement help my hair?

No supplement is permitted to claim an effect on androgen excess, and one that does is telling you to put the box down. What makes sense is correcting a deficiency you have actually measured — iron, vitamin D and zinc all appear on the list the expert committee recommends checking. Fixing a low number is worth doing. Chasing a number that is already normal is not.

Sources and references

1. Carmina E, et al. — Female Pattern Hair Loss and Androgen Excess: A Report From the Multidisciplinary Androgen Excess and PCOS Committee. Journal of Clinical Endocrinology & Metabolism, 2019;104(7):2875–2891. Consensus report on female pattern hair loss in the context of androgen excess. Most women with the frontal-central pattern have normal circulating androgens, and the same phenotype has been reported in women with no circulating androgens and in women without a functional androgen receptor; isolated hair loss of this type with normal androgen levels should not be considered hyperandrogenism. Assessment for possible androgen excess is nonetheless required in all patients; vitamin D, iron, zinc, thyroid hormones and prolactin are presented as optional but recommended. Treatment starts with 5% minoxidil, with 5-alpha-reductase inhibitors or antiandrogens added for severe hair loss or hyperandrogenism.
2. Teede HJ, Tay CT, Laven JJE, et al. — Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Journal of Clinical Endocrinology & Metabolism, 2023;108(10):2447–2469. DOI 10.1210/clinem/dgad463. International guideline, published simultaneously across several journals and updating the 2018 edition. Adult diagnosis on two of three features — oligo/amenorrhea, clinical or biochemical hyperandrogenism, polycystic ovarian morphology on ultrasound or raised AMH. Hirsutism alone is considered predictive of biochemical hyperandrogenism and of the syndrome in adults, scored with a modified Ferriman-Gallwey threshold of 4 to 6 depending on ethnicity, while female pattern hair loss and acne in isolation, without hirsutism, are relatively weak predictors of biochemical hyperandrogenism (certainty graded low). Where irregular cycles and hyperandrogenism are both present, neither ovarian ultrasound nor AMH is required for diagnosis; in adolescents neither is recommended, because of poor specificity in that age group.
3. Rayner DG, McMullen E, Mundle K, Pham M, Sibbald C, Donovan J. — Bi-directional association between female pattern hair loss and polycystic ovary syndrome: A systematic review and meta-analysis. JAAD International, 2025. DOI 10.1016/j.jdin.2025.08.004. Systematic review of twenty-four observational studies (MEDLINE, Embase and CINAHL searched to December 4, 2024). Pooled prevalence of female pattern hair loss among patients with the syndrome: 22.7% (95% CI 16.9–29.7), from 18 studies and 3,464 patients of median age 25.5 years, certainty low owing to very serious inconsistency. Pooled prevalence of the syndrome among patients presenting with female pattern hair loss: 32.3% (95% CI 13.6–59.1), from 6 studies and 1,583 patients, certainty very low. Irregular menstruation reported in 20.7% of patients with female pattern hair loss, from three studies, certainty very low.
4. Teede HJ, Bahri Khomami M, Morman R, et al. — Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. The Lancet, 2026;407:2329–2339. DOI 10.1016/S0140-6736(26)00717-8. First published online May 12, 2026. Multistep international consensus process involving more than fifty patient and professional organizations, the Endocrine Society among them, and more than twenty thousand people surveyed, replacing the name “polycystic ovary syndrome” with “polyendocrine metabolic ovarian syndrome”. The authors describe the former term as inaccurate — what ultrasound shows are not cysts — and hold it partly responsible for delayed diagnosis, fragmented care and stigma. A transition period is anticipated before general adoption. Verification note: the issue number differs between the indexes consulted and is therefore omitted here; volume and pages are those carried by the article’s own header.
5. Drug Facts, minoxidil topical aerosol foam 5% for women — over-the-counter drug labeling (United States), listings published on DailyMed (National Library of Medicine). Statements used here: do not use if your hair loss is sudden and/or patchy, if your hair loss is associated with childbirth, or if you do not know the reason for your hair loss; may be harmful if used when pregnant or breast-feeding; stop use and ask a doctor if you do not see hair regrowth in six months, or in case of chest pain, rapid heartbeat, faintness or dizziness. One labeling version states that the product will not work for all women. Wording varies slightly between packages: the carton you actually buy is the one that governs.

PubMed identifiers are not quoted in this article: direct access to PubMed and to publisher sites was blocked by the session’s network policy. Every source was verified by cross-checking several independent sources, and is cited by journal, volume, pages and DOI where one exists.